Perioperative administration of pregabalin for pain after robot-assisted
endoscopic thyroidectomy: a randomized clinical trial.
Author(s): Kim SY, Jeong JJ, Chung WY, Kim HJ, Nam KH, Shim YH.
Affiliation(s): Department of Anaesthesiology and Pain Medicine, Yonsei University College of
Medicine, 250 Seongsan-no, Seodaemun-gu, Seoul, 120-752, Republic of Korea.
Publication date & source: 2010, Surg Endosc. , 24(11):2776-81
BACKGROUND: Perioperative administration of pregabalin, which is effective for
neuropathic pain, might reduce early postoperative and chronic pain. This
randomized, double-blinded, placebo-controlled trial (Clinical Trials.gov ID
NCT00905580) was designed to investigate the efficacy and safety of pregabalin
for reducing both acute postoperative pain and the development of chronic pain in
patients after robot-assisted endoscopic thyroidectomy.
METHODS: Ninety-nine patients were randomly assigned to groups that received
pregabalin 150 mg or placebo 1 h before surgery, with the dose repeated after 12
h. Assessments of pain and side effects were performed 48 h postoperatively. The
incidences of chronic pain and hypoesthesia in the anterior chest were recorded 3
months after surgery.
RESULTS: Ninety-four patients completed the study. Verbal numerical rating scale
scores for pain and the need for additional analgesics were lower in the
pregabalin group (n = 47) than the placebo group (n = 47) during 48 h
postoperatively (P < 0.05). However, incidences of sedation and dizziness were
higher in the pregabalin group (P < 0.05). There were no differences between the
groups in the incidences of chronic pain and chest hypoesthesia at 3 months after
CONCLUSIONS: Perioperative administration of pregabalin (150 mg twice per day)
was effective in reducing early postoperative pain but not chronic pain in
patients undergoing robot-assisted endoscopic thyroidectomy. Caution should be
taken regarding dizziness and sedation.